Erythromycin, QTc interval prolongation, and torsade de pointes: Case reports, major risk factors and illness...

Area of Science:

• Pharmacology
• Cardiology
• Clinical Medicine

Background:

• Erythromycin, a macrolide antibiotic, treats various infections.
• Erythromycin use is associated with QTc interval prolongation and torsade de pointes (TdP) arrhythmia.
• Identifying risk factors for erythromycin-associated TdP is crucial for patient safety.

Purpose of the Study:

• To identify factors contributing to erythromycin-induced QTc interval prolongation and TdP.
• To analyze case reports to determine clinical risk factors.

Main Methods:

• Critical evaluation of 29 case reports (22 female, 7 male; age 18-95).
• Analysis of patient demographics, illness severity, drug administration routes, dosages, and concomitant medications.
• Assessment of potential drug interactions involving CYP3A4 and QTc-prolonging agents.

Main Results:

• No significant dose-response relationship between erythromycin and QTc duration.
• All patients presented with severe illness.
• Key risk factors identified: female sex, older age, pre-existing heart disease, and concurrent use of QTc-prolonging drugs or CYP3A4 interacting agents. Most patients had multiple risk factors.

Conclusions:

• Major risk factors for erythromycin-associated TdP include female sex, heart disease, and advanced age, particularly in severely ill patients.
• Avoid coadministration of erythromycin with CYP3A4 inhibitors/substrates or other QTc-prolonging drugs in high-risk individuals.